Please assess the completion status of the following clinical trial:

Trial Title: Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be 45 years of age or older at the time of signing the informed consent.~* Participant with AF documented by ECG evidence with~  * CHA2DS2-VASc score ≥ 2 if male or CHA2DS2-VASc score ≥ 3 if female~ * Indication for treatment with an oral anticoagulant in~    * any participant currently not treated with an oral anticoagulant (e.g. treatment naïve) or alternatively,~   * participant on a NOAC in case of at least one bleeding risk feature (history of a prior bleed within the last 12 months requiring medical attention and / or moderate renal dysfunction with eGFR 30-50 ml/min and / or current clinically indicated antiplatelet therapy with Acetylsalicylic acid(ASA) ≤ 100 mg)~* Written informed consent~Exclusion Criteria:~* Mechanical heart valve prosthesis~* Any degree of rheumatic mitral stenosis or moderate-to-severe, non-rheumatic mitral stenosis~* Atrial fibrillation due to a reversible cause, participants in sinus rhythm after successful ablation, or plan for cardioversion or ablation during study conduct~* Requirement for chronic anticoagulation (for a different indication than AF) or antiplatelet therapy (up to 100 mg ASA is allowed). Anticipated need for chronic therapy with Nonsteroidal anti-inflammatory drugs (NSAIDs)~* Treated with a Vitamin K antagonist in the 30 days prior to screening

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY2433334 50mg+Apixaban matching placebo (Type: EXPERIMENTAL): None
- BAY2433334 20mg+Apixaban matching placebo (Type: EXPERIMENTAL): None
- BAY2433334 matching placebo+Apixaban (Type: ACTIVE_COMPARATOR): Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.

Based on this trial design, predict the completion outcome and termination type (if applicable).